Viral Vector Process Development Summit

Kongressthemen
As cell and gene therapy and genomic medicine pipeline continues to mature, process development for viral vector is becoming critical for drug developers for the next phase, to deliver a quality, transformative cure to patients with affordability.

Wissenschaftliche Fach-Gesellschaft
Hanson Wade

Anmerkungen
URL:
Website: https://go.evvnt.com/1322215-3?pid=4832

Speakers: Rajiv Gangurde | Chief Technology Officer | SparingVision, Susan D'Costa | Executive VP and Global Head, Technology | Alcyone Therapeutics, and more.

https://go.evvnt.com/1322215-2?pid=4832

Frau Stephanie Nketia